Redose
Semax is a synthetic nootropic peptide with roots in Soviet-era neuroscience research. Originally derived from a fragment of adrenocorticotropic hormone (ACTH), it has been used clinically in Russia and Ukraine for neurological indications for several decades while remaining an investigational compound in most of the rest of the world. Interest in Semax has grown outside its country of origin primarily because of its reported effects on brain-derived neurotrophic factor (BDNF) and cognitive function.
What is Semax
Semax is a heptapeptide, a chain of seven amino acids, with the sequence Pro-Gly-Pro-Arg-Gly-Lys-Pro. It was synthesized at the Institute of Molecular Genetics in Moscow, Russia, beginning in the 1980s, based on the ACTH(4-10) fragment. Researchers modified the parent fragment to improve metabolic stability, resulting in a compound that resists rapid breakdown by peptidases in plasma and tissues.
In Russia and Ukraine, Semax holds regulatory approval and is available as a prescription nasal spray under the brand names Semax and Mexidol-Semax, among others. Approved indications include ischemic stroke, transient ischemic attack, and certain forms of cognitive impairment. In the United States, European Union, and most other countries, Semax has no approved status and is classified as a research or investigational compound.
How it works
Semax's proposed mechanisms have been studied in both cell culture experiments and animal models. The picture that emerges is of a compound acting on multiple overlapping neurological pathways:
- BDNF and NGF upregulation: Semax consistently increases the expression of brain-derived neurotrophic factor and nerve growth factor in preclinical studies. BDNF in particular plays a central role in neuronal plasticity, learning and memory consolidation, and recovery from brain injury. This is considered the most pharmacologically significant finding in the Semax literature.
- Melanocortin receptor activity: Semax retains partial activity at melanocortin receptors (MC4R and MC5R), which are involved in anti-inflammatory signaling and energy regulation within the central nervous system.
- Enkephalin metabolism: Semax appears to inhibit enzymes (leucine enkephalin aminopeptidase and proline endopeptidase) that break down enkephalins, endogenous opioid peptides involved in pain modulation and mood. Preserving enkephalin activity may contribute to its reported anxiolytic and mood-related effects.
- Dopamine and serotonin modulation: Animal studies have reported changes in the activity of dopaminergic and serotonergic systems, which may underlie reported improvements in attention and motivation.
- Anti-inflammatory CNS effects: Research in rodent models of hypoxia and stroke has shown reductions in markers of central nervous system inflammation following Semax administration, which aligns with its use in stroke rehabilitation protocols.
These mechanisms are not fully characterized in human subjects. Most detailed mechanistic work comes from Russian research groups and preclinical animal studies.
What the research says
The Semax evidence base is unusual in that it includes a meaningful volume of clinical research conducted in Russia, alongside the more typical body of preclinical rodent studies. However, most of this human research has not been independently replicated in large randomized controlled trials conducted outside Russia, which limits how confidently findings can be generalized.
| Area | Summary of findings |
|---|---|
| Ischemic stroke | Russian clinical trials have reported improved neurological recovery scores and reduced inflammation in patients receiving Semax alongside standard care |
| Cognitive impairment | Some trials in patients with mild cognitive disorders report improvements in attention and memory tasks |
| Hypoxia tolerance | Rodent studies consistently show reduced neuronal damage after oxygen deprivation when Semax is given prior to or shortly after the hypoxic event |
| Anxiety and stress | Animal models report dose-dependent anxiolytic effects; human data are very limited |
| Memory and learning | Rodent studies report enhanced spatial memory and learning in maze tasks; human nootropic use is based largely on extrapolation from these findings |
The most robust human evidence comes from the stroke and cerebrovascular domain, where Semax has been used as an adjunct treatment in Russian hospitals for years. The nootropic applications, which have driven most of the English-language interest, rest on weaker human evidence and are largely extrapolated from animal research and anecdotal reports from users in wellness and biohacking communities.
For a broader perspective on how peptides differ in their evidence strength and route of administration, see the injection site rotation guide for notes on subcutaneous techniques, or the reconstitution guide for preparation steps.
Typical dosing
There is no standardized, clinically validated dosing protocol for Semax outside of Russian medical practice. The ranges below are drawn from published Russian clinical trials, preclinical literature, and commonly reported wellness protocols. They are reference information only, not medical instructions.
| Route | Reported range | Reported frequency | Notes |
|---|---|---|---|
| Intranasal spray | 300-600 mcg per day | Once or twice daily | Most common reported route; each nostril delivers one spray per dose |
| Subcutaneous injection | 100-500 mcg per day | Once daily | Less common; used when intranasal bioavailability is a concern |
Reported cycle lengths in wellness contexts range from a few days for acute cognitive support to several weeks for neuroprotection or recovery protocols. Russian clinical use in stroke patients typically runs 5-14 days as an acute intervention. There is limited data on effects of prolonged daily use.
Semax is typically stored in a refrigerator and, when in lyophilized powder form, must be reconstituted before use. The reconstitution guide covers the process in detail.
As with any peptide protocol, the dosing context matters. Dosing should always be discussed with a qualified healthcare provider familiar with your history and goals.
Side effects and safety
Published Russian clinical reports describe Semax as generally well tolerated. The most commonly noted adverse effects are mild:
- Nasal irritation, mild burning, or discomfort at the site of administration (intranasal route)
- Transient headache, particularly in early use
- Mild fatigue or changes in energy levels, which some users report as dose-dependent
- Occasional reports of mood changes or increased irritability
Serious adverse events have not been prominently reported in the published clinical literature, but this should be interpreted cautiously. The trials conducted in Russia were generally small and not always conducted to modern randomized controlled trial standards. Large, independently conducted, long-term safety studies do not exist. This means that rare or delayed adverse effects remain uncharacterized.
Semax is not listed as a controlled substance in the US or EU, but it also has no approved prescription status in those regions. Its legal status as a research compound varies by jurisdiction, and it is not available through regulated pharmacy channels in most countries outside Russia.
Tracking Semax with Redose
Semax protocols, whether intranasal or injected, benefit from consistent tracking. Redose makes it easy to log each dose in a single tap, build a full dose history, and set reminders so you never lose your place in a cycle. The inventory tracker shows exactly how many doses remain in your current vial or bottle, and the calculator at /calculators handles reconstitution math if you are working from lyophilized powder. Download the app at /#download to get started.
This profile is educational information, not medical advice. Talk to a qualified healthcare provider before starting any protocol.